Robert Matlack, MD
Psychiatry · Fayetteville, NCNPI 1700881190
Payments from drug & device makers
Across 217 payments — averaging $13.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$414
- Otsuka America Pharmaceutical, Inc.$392
- Takeda Pharmaceuticals U.S.A., Inc.$233
- Sunovion Pharmaceuticals Inc.$231
- Alkermes, Inc.$218
- Tris Pharma Inc$193
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,915100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $414 |
| Otsuka America Pharmaceutical, Inc. | 20 | $392 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $233 |
| Sunovion Pharmaceuticals Inc. | 18 | $231 |
| Alkermes, Inc. | 10 | $218 |
| Tris Pharma Inc | 14 | $193 |
| Supernus Pharmaceuticals, Inc. | 38 | $160 |
| Neos Therapeutics, LP | 8 | $140 |
| Ironshore Pharmaceuticals Inc. | 8 | $133 |
| Lundbeck LLC | 6 | $126 |
| Neurocrine Biosciences, Inc. | 5 | $88 |
| Adlon Therapeutics L.p. | 5 | $81 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $75 |
| Johnson & Johnson | 5 | $67 |
| Vanda Pharmaceuticals Inc. | 3 | $48 |
| Vertical Pharmaceuticals, LLC | 1 | $41 |
| Shire North American Group Inc | 3 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Corium, LLC | 2 | $34 |
| Bausch Health US, LLC | 2 | $32 |
| Merck | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| OWP Pharmaceuticals, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $15 |
| Rhodes Pharmaceuticals L.p. | 1 | $14 |
| Noven Therapeutics, LLC | 1 | $12 |
| Aytu Biopharma, Inc. | 1 | $11 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$2,915 in reported general payments places this provider in the 80th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 162 | $252,012 |
| FanaptIloperidone | 84 | $112,351 |
| RexultiBrexpiprazole | 55 | $110,682 |
| TrintellixVortioxetine Hydrobromide | 148 | $81,107 |
| Invega SustennaPaliperidone Palmitate | 12 | $39,891 |
| Tiagabine Hcl | 98 | $36,614 |
| CaplytaLumateperone Tosylate | 17 | $27,483 |
| Aripiprazole | 347 | $26,780 |
| Chlorpromazine Hcl | 65 | $22,735 |
| VyvanseLisdexamfetamine Dimesylate | 52 | $21,022 |
| ConcertaMethylphenidate Hcl | 32 | $14,814 |
| Lurasidone Hcl | 163 | $14,514 |
| FetzimaLevomilnacipran Hcl | 18 | $8,686 |
| BelsomraSuvorexant | 18 | $8,231 |
| DayvigoLemborexant | 24 | $8,116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $414 | $260,699180 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $48 | $112,35184 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $392 | $110,68255 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $233 | $102,129200 claims |
| Johnson & JohnsonInvega Sustenna, Concerta | $67 | $54,70544 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $75 | $27,48317 claims |
| MerckBelsomra | $26 | $8,23118 claims |
| Eisai Inc.Dayvigo | $15 | $8,11624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Fayetteville
- Craig ChepkeHuntersville$4.1M
- James BarkerHickory$4.1M
- Mark ReynoldsDurham$3.2M
- Oleg TcheremissineCharlotte$2M
- Richard WeislerRaleigh$1.2M
- Dan BlazerDurham$1M
- Samantha Meltzer-BrodyChapel Hill$909K
- Andrew KrystalDurham$754K
- Brian FarahWinston Salem$605K
- Krishna TalluriMorrisville$591K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.